Biotech catalyst, news and analysis PDUFA tracker
Tickers reports and analysis
ASCO and EULAR are about to put three very different clinical stories in front of investors: a registrational ALK lung-cancer dataset already used for an NDA submission, an early solid-tumor CAR-T update from a commercial cell-therapy company, and a Phase 3 autoimmune dataset that could shape an upcoming regulatory filing.
A single-stock May 2026 review of Artelo’s story from the earlier CAReS and FABP5 setup to the latest Q1 business update, the ScienceMachine collaboration, the glaucoma expansion, the GLP-1 companion angle, the $11 million financing, the Nasdaq compliance repair and the still-visible common-equity risks.
The week ahead starts with U.S. markets closed for Memorial Day on Monday, May 25, then moves quickly into a dense calendar: Consumer Confidence, Marvell, Salesforce, Snowflake, Synopsys, Dell, Costco, GDP, durable goods and the Fed’s preferred inflation gauge. The setup is constructive but fragile: AI infrastructure remains the leadership engine, Iran/Hormuz headlines can move oil and inflation expectations, and Kevin Warsh’s first days at the Fed put rate sensitivity back at the center of the tape.
Natera has moved far beyond the simple label of a prenatal genetic-testing company. The 2026 story is now a scaled precision-diagnostics platform built around oncology MRD, women’s health, organ transplant monitoring, rare-disease genomics, data generation, reimbursement expansion, and industrial-scale sequencing infrastructure.
The Bundibugyo Ebola outbreak is pushing public-health preparedness back into focus. GeoVax and Co-Diagnostics have fresh Ebola-linked updates, while RedHill belongs in the same theme through earlier Ebola antiviral research and BARDA-supported opaganib development, but not as a same-day outbreak catalyst.
Silexion is trying to move a second-generation siRNA therapy into a Phase 2/3 program for locally advanced pancreatic cancer. The scientific story is focused and potentially interesting; the trading story is extremely high-risk because cash, Nasdaq compliance, dilution and execution now matter almost as much as the biology.
MetaVia is trying to place itself inside one of the hottest areas in biotech: obesity, MASH and next-generation cardiometabolic drugs. The story is interesting because DA-1726 has early human weight-loss data and fresh ADA visibility. The story is dangerous because the company is tiny, cash is limited, dilution risk is real, and the next major value test is still clinical execution, not social-media excitement.
Regeneron Pharmaceuticals is not a fragile biotech story. It is one of the most successful U.S. biotechnology companies of the last two decades, with a deep research culture, internally built technology platforms, a historic ophthalmology franchise around Eylea, a massive immunology engine through Dupixent with Sanofi, and a growing ambition in oncology. That is exactly why the latest melanoma setback matters. The issue is not whether Regeneron can survive one failed study. The real question is
Merlintrader Deep Dive Updated May 18, 2026 Biotech / Immuno-Oncology BriaCell Therapeutics Corp. (Nasdaq: $BCTX): Phase 3 Breast Cancer, ASCO 2026 And A Rapid Pipeline Expansion BriaCell is no longer only a tiny Phase 3 metastatic breast cancer binary. Since the last Merlintrader deep dive, the company has added new clinical sites, reported a larger […]
Fortress Biotech is one of the more unusual stories in the U.S. small-cap biotech universe because it should not be analyzed like a normal single-drug development company. FBIO is a biopharma platform that creates, finances, controls or participates in multiple companies and programs, trying to monetize value through product revenue, royalties, milestones, asset sales, equity stakes and strategic transactions. That structure makes the stock more complicated than a classic biotech catalyst trade.
Microbot Medical is not a clean “robotics stock” headline. It is a much more interesting, messier and more human story: a small public medical device company trying to commercialize a remotely operated, single-use robotic system for endovascular procedures, while the market debates whether the first commercial signs are meaningful enough to justify the risk. The company has now reported first-quarter 2026 revenue tied to the limited market release of LIBERTY, says Q2 revenue had already exceeded Q1 revenue by mid-quarter, and has scheduled a May 18 investor call where real physician users of the system are expected to join management.
Merlintrader Biotech Update Published / Aggiornato: May 15, 2026 $TRAWDaily chart $GALTDaily chart $MSLEDaily chart $TRAW $GALT $MSLE Biotech May 15 Updates Viral Threats, Liver Fibrosis and Muscle Regeneration: $TRAW, $GALT and $MSLE Add Another Layer to the May 15…
The final May 15 biotech group is not built around early proof-of-concept excitement. It is built around regulatory execution, pivotal-stage risk and the constant question that follows small and mid-sized biotech companies: can the next regulatory or clinical milestone arrive before financing pressure becomes the dominant market narrative? aTyr Pharma, BioXcel Therapeutics and Moleculin Biotech all issued updates on May 15 that give traders and long-form biotech readers a concrete catalyst map, but each company also comes with a very different risk profile.
The May 15 biotech tape delivered another group of earnings and business updates that deserve more than a quick headline scan. Annovis Bio pushed its neurodegenerative disease story forward with a Phase 3 Alzheimer’s update, 85% enrollment in its pivotal Alzheimer’s disease trial, a positive DSMB safety recommendation, a Parkinson’s open-label extension study now 40% enrolled, and an outlined NDA path for buntanetap. Immuneering reported a very different type of update, centered on atebimetinib in pancreatic cancer, an upcoming ASCO oral presentation, a pivotal Phase 3 MAPKeeper 301 trial now recruiting, and a strong cash position of $198.6 million expected to fund operations into 2029. MiNK Therapeutics added a smaller but clinically interesting cell-therapy angle, advancing its off-the-shelf iNKT platform into randomized Phase 2 validation in severe acute lung injury and critical illness, with additional clinical data scheduled for ATS on May 20.
Clinical Signals, Commercial Execution and Regulatory Paths: $TNYA, $SPRY and $BCDA After the May 15 Updates
Innate Pharma static chart — IPHA Static Finviz image. Referral applies only if the chart is clicked. The image is loaded without an affiliate parameter. The affiliate referral is attached only to the outbound chart link. Merlintrader Stock Hub ·…
Static Finviz chart. Affiliate referral is attached only to the outbound chart link, not to the image load. Latest Insight · May 14, 2026 Nasdaq: $CING Q1 2026 · FDA Catalyst Cingulate Inc. (Nasdaq: $CING): Q1 Cash Build, Commercial Readiness…
REGENXBIO, Cabaletta Bio and Karyopharm all reported first-quarter 2026 updates on the same day, but the investment debate is not simply about quarterly EPS. The real story is a cluster of catalyst paths: Duchenne gene therapy and AbbVie-partnered retinal disease at REGENXBIO, rese-cel autoimmune cell therapy at Cabaletta, and a selinexor franchise trying to extend beyond multiple myeloma at Karyopharm.
The May 2026 biotech earnings window produced three very different stories in Precigen, Aquestive Therapeutics and Allogene Therapeutics. They belong to the same broad sector, they all sit inside the volatile small-to-mid-cap biotechnology universe, and they all trade with catalyst sensitivity.
May 13 delivered another packed biotech earnings and business-update session. For traders, the hard part is not simply finding companies that issued a press release. The hard part is separating routine quarterly updates from updates that actually change the near-term story. The three names in this article — Tyra Biosciences, Spruce Biosciences and PDS Biotech — all fit that second category, but for very different reasons.
